Archive: 30/10/2017
Tazemetostat shows early promise for children with certain relapsed or refractory solid tumors
Children with relapsed or refractory malignant rhabdoid tumors, epithelioid sarcomas, or poorly differentiated chordomas with a particular genetic defect tolerated treatment with the investigational drug tazemetostat well ...
Oct 30, 2017
Number of seamless clinical trials in oncology has risen recently
The number of early-phase trials in oncology that adopted a seamless approach, as opposed to a traditional trial approach with defined phase I, II, and III plans, is rising, with data from the majority of them presented after ...
Oct 30, 2017
Moving neuroscience into the fast lane
At the RIKEN Brain Science Institute in Japan, a two-year project from Andrea Benucci's research group has culminated in the construction and deployment of a high-throughput system to study mouse behavior and physiology. ...
Oct 30, 2017
Colorectal cancers may mutate to escape immune system detection in many ways
Whole exome sequencing revealed that colorectal cancers with high mutational load (MSI-H) predominantly use "immunoediting" to escape immune surveillance while colorectal cancers with low mutational load (MSS) use oncogenic ...
Oct 30, 2017